Get the Stockscreener App
62.17
1.19%
-0.75
After Hours:
61.33
-0.84
-1.35%
Hologic Inc stock is traded at $62.17, with a volume of 5.38M.
It is down -1.19% in the last 24 hours and up +6.53% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$62.92
Open:
$62.75
24h Volume:
5.38M
Relative Volume:
1.54
Market Cap:
$13.85B
Revenue:
$4.03B
Net Income/Loss:
$556.70M
P/E Ratio:
26.23
EPS:
2.37
Net Cash Flow:
$970.10M
1W Performance:
+14.54%
1M Performance:
+6.53%
6M Performance:
-21.80%
1Y Performance:
-14.34%
1-Day Range:
$61.85
$62.92
1-Week Range:
$54.52
$68.25
52-Week Range:
$51.90
$84.67
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
62.17 | 12.10B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock - sharewise
Digital X-ray Devices Market Is Booming So Rapidly 2025-2032Hologic, Inc., Hitachi, Ltd., Siemens Healthineers - openPR.com
Hologic turns down USD 16.7B non-binding offer from TPG, Blackstone - Medical Buyer
Blackstone (NYSE:BX) and TPG Eye US$16 Billion Hologic Buyout in Rejected Offer - simplywall.st
Hologic is reportedly a private equity takeover target - MassDevice
Hologic (HOLX) Surges 23% After Trade Resumption | HOLX Stock Ne - GuruFocus
Global markets live: Nvidia, General Motors, Hologic, Chevron, Stellantis… - marketscreener.com
Forecasting The Future: 6 Analyst Projections For Hologic - Benzinga
Needham Reiterates Hold Rating for Hologic (HOLX) | HOLX Stock News - GuruFocus
Q1 Earnings Outperformers: Hologic (NASDAQ:HOLX) And The Rest Of The Medical Devices & SuppliesImaging, Diagnostics Stocks - Yahoo Finance
Why Hologic, Inc. (HOLX) Went Up On Tuesday - MSN
Healthcare Stocks Higher -- Healthcare Roundup - marketscreener.com
Hologic Inc. stock outperforms competitors on strong trading day - MarketWatch
Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. - Barron's
Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday? - Benzinga
Hologic (HOLX) Surges Following Take Private Offer Report | HOLX Stock News - GuruFocus
Hologic reportedly rejects $16B go-private offer from TPG, Blackstone - Proactive financial news
Hologic shares surge on reported buyout approach By Investing.com - Investing.com Nigeria
Hologic (HOLX) Shares Surge on Private Equity Interest - GuruFocus
Hologic shares surge on reported buyout approach - Investing.com Australia
Blackstone (BX) Involved in Rejected Hologic Acquisition Bid | B - GuruFocus
Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone - marketscreener.com
Hologic rejects over $16 billion take-private proposal from TPG and Blackstone, FT reports - 1470 & 100.3 WMBD
Blackstone (BX) Eyes Hologic in $16 Billion Privatization Offer - GuruFocus
Wall Street Rockets As Bond Yields Drop, Tesla Hits 3-Month Highs: What's Driving Markets Tuesday? - Benzinga
Why Is Hologic (HOLX) Stock Rocketing Higher Today - Yahoo Finance
Blackstone (BX) Considers Buying Hologic in $16B Deal | BX Stock News - GuruFocus
Hologic stock rises after take-private offer (HOLX:NASDAQ) - Seeking Alpha
Hologic jumps after report of rejected $16 bln TPG-Blackstone buyout offer - TradingView
Blackstone (BX) Eyes Potential Acquisition of Hologic in Multi-B - GuruFocus
Blackstone, TPG said to offer $16B to buy Hologic - breakingthenews.net
Hologic's Shares Jump On $16 Billion Buyout Bid - Finimize
Hologic (HOLX) Surges 23% After Trade Resumption | HOLX Stock News - GuruFocus
Blackstone (BX) Eyes Potential Acquisition of Hologic in Multi-Billion Dollar Deal | BX Stock News - GuruFocus
Blackstone, TPG Offer $16 Billion to Take Hologic Private - marketscreener.com
Prostate Biopsies Device Market May See a Big Move | Major Giants- Medtronic, Intuitive Surgical, Hologic - openPR.com
Blackstone, TPG Offer to Take Hologic Private in $16 Billion Deal, Financial Times Reports - marketscreener.com
Blackstone, TPG Offer $16 Billion to Take Hologic Private, Financial Times Reports - marketscreener.com
TPG And Blackstone Offered $16 Bln To Take Health Group Hologic PrivateFT - marketscreener.com
TPG and Blackstone offered $16bn to take health group Hologic private - Financial Times
Future Scope of Breast Density Assessment Software Market - openPR.com
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick? - Yahoo Finance
BNP Paribas Exane Adjusts Price Target on Hologic to $71 From $85, Maintains Outperform Rating - marketscreener.com
Hologic (NASDAQ:HOLX) stock falls 3.8% in past week as three-year earnings and shareholder returns continue downward trend - simplywall.st
Hologic’s SWOT analysis: medical tech firm faces growth hurdles, stock outlook mixed - Investing.com
How Hologic Stabilized Its Breast Health Business & Is Positioned for Explosive Growth! - Smartkarma
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients - BioSpace
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
14.61%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):